Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals plc director Heather Ann McSharry reported an open-market sale of 2,000 Ordinary Shares of the company on May 22, 2026 at a price of $241.00 per share. After this transaction, she directly holds 18,449 Ordinary Shares of Jazz Pharmaceuticals.
Filer submitted a Form 144 to propose the sale of 2,000 shares of Common Stock. The filing lists a cash amount of $482,000.00 and an identifier 62742820 with an execution date of 05/22/2026.
The excerpt shows two tranches of restricted stock with grant dates and quantities: 667 shares dated 08/07/2015 and 1,333 shares dated 05/11/2015. The filing notes these securities are to be sold and records no reported sales in the past three months in the provided excerpt.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of Jazz Pharmaceuticals on May 1, 2026, at $203.33 per share. After this transaction, he directly holds 378,682 Ordinary Shares.
According to the filing, this sale was executed automatically under a pre-arranged trading plan adopted on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, meaning the timing did not involve a discretionary decision by Cozadd.
Jazz Pharmaceuticals reported sharply improved results for the quarter ended March 31, 2026. Total revenues rose to $1,068.9 million from $897.8 million, driven by higher product sales across sleep, epilepsy and oncology franchises.
Net income reached $293.1 million, compared with a net loss of $92.5 million a year earlier, helped by a $122.8 million gain on the sale of a rare pediatric disease priority review voucher and lower selling, general and administrative expenses. Cash and cash equivalents increased to $1,844.3 million, while total debt remained around $5.35 billion, leaving the company with significant liquidity to support its rare disease portfolio and R&D pipeline.
Jazz Pharmaceuticals reported strong first-quarter 2026 results, with total revenues of $1.07 billion, up 19% year over year, and GAAP diluted EPS of $4.43 versus a loss a year ago. Non-GAAP adjusted EPS was $6.34, and cash from operations reached $408 million.
Growth was driven by key products, including Xywav (up 18% to $408 million), Epidiolex/Epidyolex (up 15% to $249.8 million) and Zepzelca (up 60% to $101 million), plus initial Modeyso sales. The company ended March 31, 2026 with $2.9 billion in cash, cash equivalents and investments and $5.4 billion in long-term debt principal.
Jazz completed the sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of $200 million (50% to Jazz), and reaffirmed its full-year 2026 total revenue guidance of $4.25–$4.5 billion along with both GAAP and non-GAAP margin and expense outlook.
Jazz Pharmaceuticals (Rule 144 notice): The filing reports sales of restricted common stock in lots of 6,000 shares. Two sale entries are shown with trade dates 03/03/2026 and 04/01/2026, each for 6,000 shares, with numeric amounts listed alongside those rows.
Jazz Pharmaceuticals PLC ownership filing shows Vanguard Capital Management reports beneficial ownership of 3,103,522 shares of common stock, representing 5.04% of the class. The filing lists sole voting power for 455,189 shares and sole dispositive power over 3,103,522 shares. The signature date on the filing is 04/30/2026.
Jazz Pharmaceuticals plc filed an Amendment No. 1 to its 2025 annual report to add Part III information normally drawn from its proxy, update the cover page and exhibit list, and provide new CEO/CFO certifications. The company reported an aggregate market value of non‑affiliate equity of about $6.25 billion as of June 30, 2025, and 62,738,815 ordinary shares outstanding as of April 15, 2026.
Jazz highlights record 2025 performance with strong product sales, including Xywav $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million, plus oncology contributions from Zepzelca, Rylaze/Enrylaze, Modeyso and Ziihera. The board describes a pay‑for‑performance design: 2025 bonuses funded at 150% of target based on corporate goals, while 2023–2025 PSUs paid at 94% of target after operational scoring and relative TSR adjustments.
The amendment details a staggered board, refreshed committee memberships and extensive biopharma, financial and governance experience among directors and executives. It also outlines executive incentives tied to multi‑year commercial, pipeline and capital deployment objectives, supported by stock ownership guidelines, a clawback policy, insider‑trading controls and change‑in‑control and severance plans.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 ordinary shares of the company in open-market transactions. The sales occurred on 2026-04-01 at weighted average prices of $190.2220, $190.9383 and $191.7447 per share. According to a footnote, these trades were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was not discretionary. After the transactions, Cozadd directly owned 384,682 ordinary shares of Jazz Pharmaceuticals.